A cancerous mole, almost always a melanoma, sets off a chain of medical events that begins with a biopsy and can extend through surgery, lymph node evaluation, and sometimes systemic drug therapy. How far that chain goes depends largely on how deep the cancer has grown into the skin by the time it is caught. Caught early and thin, a cancerous mole is usually cured with a single outpatient surgery. Caught late or thick, it can spread to distant organs and require aggressive treatment. The biology in between those two endpoints is where most of the decisions, uncertainty, and progress in melanoma medicine sit today.
How a Cancerous Mole Gets Flagged
The first step is usually visual. Dermatologists and primary care doctors screen moles using the ABCDE criteria: Asymmetry, irregular Borders, multiple Colors, a Diameter larger than about 6 millimeters, and Evolution (any change over time). These criteria are not a diagnosis; they are a triage tool that tells a clinician whether a mole deserves a closer look. A systematic review of clinical prediction rules found that the ABCD dermoscopy rule, when used with a handheld dermatoscope, had a pooled sensitivity of about 85% and a specificity of about 72%, meaning it catches most melanomas but also flags a fair number of harmless lesions.1BMJ Open. Diagnosing malignant melanoma in ambulatory care: a systematic review of clinical prediction rules That tradeoff is intentional. Missing a melanoma is far worse than removing an extra benign mole, so the screening is designed to err on the side of caution.
Dermoscopy, which uses a magnifying lens and polarized light to see structures beneath the skin’s surface, has become standard in most dermatology practices and even in some telemedicine setups.2PubMed Central. Teledermoscopy for Skin Cancer Prevention: a Comparative Study of Clinical and Teledermoscopic Diagnosis Artificial intelligence tools trained on dermoscopic images have also entered the picture, performing at least as well as experienced dermatologists in head-to-head comparisons, with mean sensitivity around 83% and specificity around 86%.3PubMed Central. Analysis of Artificial Intelligence-Based Approaches Applied to Non-Invasive Imaging for Early Detection of Melanoma: A Systematic Review These algorithms are not replacing doctors yet, but they are becoming a useful second opinion, particularly in settings where dermatology expertise is scarce.
What Happens During the Biopsy
If a mole looks suspicious, the next step is removing all or part of it and sending it to a pathologist. The gold standard is an excisional biopsy, where the entire lesion is cut out with a small margin of normal skin. This gives the pathologist a complete specimen to measure and evaluate. In practice, though, many suspicious moles get a shave biopsy instead, where a blade slices off the raised portion. Shave biopsies are quicker and leave smaller scars, but they have a well-documented downside: because they do not always capture the deepest part of the mole, they can underestimate how thick a melanoma really is.
A systematic review and meta-analysis found that shave biopsies have a high rate of positive deep margins, meaning cancer cells reach the bottom edge of the sample. That can complicate planning for the next surgery. However, the same review concluded that this problem translates to a relatively small number of patients who are actually upstaged or who need a different treatment plan as a result, and no measurable impact on recurrence or survival was found.4PubMed Central. Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis So while excision is preferred, a shave biopsy is not a disaster if it is what your doctor performed initially.
Reading the Pathology Report
Once the biopsy specimen reaches a pathologist, the most important measurement they take is the Breslow thickness, the distance in millimeters from the top of the skin to the deepest point the melanoma cells have reached. This single number drives nearly every treatment decision that follows. It determines how wide the follow-up surgical excision needs to be, whether a sentinel lymph node biopsy is recommended, and how the cancer is staged.
The pathologist also looks for ulceration, which means the skin surface over the tumor has broken down. An ulcerated melanoma tends to behave more aggressively than a non-ulcerated one of the same thickness. Other details in the report include the mitotic rate (how fast the cells are dividing) and whether the margins of the excised tissue are clear of cancer cells. The relationship between thickness and outcome is strong but not absolute: some thin melanomas still metastasize, and some thick ones do not.5PubMed Central. The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients That unpredictability is part of why oncologists layer additional tests on top of the biopsy rather than relying on thickness alone.
The Wider Excision Surgery
After a melanoma diagnosis, the standard treatment is a wide local excision, a second surgery to remove additional tissue around the original biopsy site. The goal is to clear any microscopic cancer cells that may have been left behind. How much surrounding skin gets taken depends on the Breslow thickness:
- In situ (confined to the top layer): 5 mm margin
- Less than 1.0 mm thick: 1 cm margin
- 1.0 to 4.0 mm thick: 1 to 2 cm margin
- Greater than 4.0 mm thick: 2 cm margin
These guidelines come from Australian and New Zealand clinical practice recommendations and are broadly consistent with international standards.6Australian Family Physician. Melanoma A management guide for GPs A systematic review comparing wide margins (3 to 5 cm) with narrower ones (1 to 2 cm) found no difference in overall survival, disease-free survival, or local recurrence, confirming that 1 to 2 cm margins are sufficient for most melanomas on the trunk or extremities.7PubMed Central. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis This is good news for patients: smaller margins mean less tissue removed, smaller scars, and simpler wound closures, all without sacrificing safety.
For most people with a thin melanoma, this surgery is the end of treatment. The wound heals, and the patient enters a follow-up schedule of regular skin checks. The entire process from biopsy to complete excision can be wrapped up in a few weeks.
Sentinel Lymph Node Biopsy
When a melanoma is thicker, doctors need to know whether cancer cells have started traveling through the lymphatic system. The sentinel lymph node biopsy, or SLNB, answers that question. A radioactive tracer or blue dye is injected near the melanoma site, and the first lymph node it drains to (the “sentinel” node) is identified and surgically removed for examination. This procedure has been used for nearly 30 years and provides staging information with relatively low risk of complications.8PubMed Central. Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View
Whether you need an SLNB depends on your melanoma’s characteristics. Current guidelines from the American Society of Clinical Oncology and the Society of Surgical Oncology recommend against routine SLNB for very thin, non-ulcerated melanomas (under 0.8 mm). For melanomas between 0.8 and 1.0 mm, or thinner ones that are ulcerated, SLNB may be discussed as an option. For intermediate-thickness melanomas (roughly 1 to 4 mm), SLNB is recommended. For very thick melanomas (over 4 mm), it may still be recommended after weighing the benefits and risks.9PubMed. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update
If the sentinel node comes back negative, the cancer has not spread to the lymph nodes, which is a reassuring finding. If it comes back positive, the melanoma is upstaged, and additional treatment, usually systemic therapy rather than further lymph node surgery, enters the picture. Researchers have noted that negative sentinel nodes are common even in deep melanomas, leading to ongoing discussions about whether the criteria for recommending SLNB should be refined to spare some patients an unnecessary procedure.10PubMed Central. Redesigning Sentinel Lymph Node Biopsy Guidelines in Melanoma Cases
When Melanoma Spreads
Melanoma’s reputation for danger comes largely from its ability to metastasize, or spread to organs far from the original skin site. When it does spread, the most common destination in the abdomen and pelvis is the liver, followed by pelvic lymph nodes. The primary tumor’s location influences where it goes: melanomas on the lower extremities have the highest rate of abdominal or pelvic spread, and ocular and head-and-neck melanomas show a strong preference for the liver.11PubMed Central. Melanoma metastases in the abdomen and pelvis: Frequency and patterns of spread Melanoma also frequently metastasizes to the brain, and brain metastases remain one of the leading causes of death in melanoma patients because they are especially difficult to treat.12PubMed Central. Personalized identification and characterization of genome-wide gene expression differences between patient-matched intracranial and extracranial melanoma metastasis pairs
Other metastatic sites include the lungs, bones, and subcutaneous tissue. The pattern is not always predictable: about 14% of patients with metastatic disease develop deposits in atypical locations like the spleen.11PubMed Central. Melanoma metastases in the abdomen and pelvis: Frequency and patterns of spread This tendency to pop up in unexpected places is one reason follow-up imaging and monitoring are taken seriously after a melanoma diagnosis.
How Immunotherapy Changed the Outlook
Before about 2011, a diagnosis of advanced melanoma was grim. Chemotherapy worked poorly, and survival was measured in months. The arrival of immune checkpoint inhibitors transformed that picture. These drugs work by removing the brakes that melanoma cells put on the immune system, allowing the body’s own T cells to recognize and attack the tumor. The first such drug, ipilimumab (which blocks CTLA-4), was the first agent ever shown to improve overall survival in advanced melanoma. Drugs targeting PD-1, such as pembrolizumab and nivolumab, followed and proved even more effective, producing durable responses in a higher proportion of patients.13Clinical Cancer Research. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Combination immunotherapy, using both a CTLA-4 inhibitor and a PD-1 inhibitor together, can be more effective but also more toxic. A real-world study found that for most patients with disease limited to two or fewer organ systems, PD-1 monotherapy actually provided better survival than the combination. In contrast, patients whose melanoma had spread to three or more organ systems saw a clear benefit from combination treatment, with three-year survival rates of about 35% versus 18% on monotherapy alone.14BJC Reports. Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study This kind of nuance matters: more treatment is not always better, and matching the intensity of therapy to the extent of disease is a central challenge.
Not everyone responds to immunotherapy, though. A significant subset of melanoma patients remain unresponsive to checkpoint inhibitors, and researchers are actively searching for biomarkers that can predict who will benefit. Tumor mutation burden, a measure of how many genetic changes the cancer carries, is one promising predictor: patients with higher mutation burdens tend to respond better and survive longer on combined immunotherapy.15PubMed Central. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
Targeted Therapy for BRAF-Mutant Melanoma
Roughly 40% to 60% of melanomas carry a specific mutation in the BRAF gene, most commonly the V600E variant. This mutation locks a growth-signaling pathway into the “on” position, fueling tumor growth.16PubMed Central. Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression For patients whose tumors test positive for this mutation, targeted drugs that block BRAF and its downstream partner MEK are a treatment option. The combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) is widely used as a first-line option for advanced BRAF-mutant melanoma and is generally well-tolerated.17PubMed Central. Trametinib: A Targeted Therapy in Metastatic Melanoma18PubMed. Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy
These targeted drugs often produce rapid tumor shrinkage, which can be especially valuable when melanoma is causing immediate symptoms like pain or organ compression. The catch is that resistance often develops within a year or two, as the cancer finds alternate growth pathways. Immunotherapy tends to produce slower but more durable responses. For this reason, oncologists increasingly face a strategic choice: start with immunotherapy for long-term disease control or start with targeted therapy for fast relief, sometimes sequencing one after the other.
Neoadjuvant Therapy Before Surgery
One of the most exciting recent developments is the use of immunotherapy before surgery rather than only after it. In a landmark trial, patients with advanced but still surgically removable melanoma were randomized to receive pembrolizumab either before and after surgery or only after surgery. At two years, the group that received immunotherapy before surgery had an event-free survival rate of 72%, compared to 49% in the group that received it only afterward.19PubMed Central. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma The logic is intuitive: giving the immune system a head start against the tumor while it is still in the body allows T cells to encounter the full spectrum of cancer proteins before surgery removes that target.
This approach is shifting clinical practice for patients with larger or node-positive melanomas. It is not yet standard for thin, early-stage disease, where surgery alone remains curative in the vast majority of cases.
Life After Treatment
Surviving melanoma does not mean the story is over. Melanoma survivors have roughly a nine-fold increased risk of developing a second, entirely separate melanoma compared to the general population, and that elevated risk persists for more than 20 years after the initial diagnosis.20PubMed Central. Increased risk of second primary cancers after a diagnosis of melanoma About a quarter of second cancers in melanoma survivors are new primary melanomas rather than recurrences of the original one. Reassuringly, second melanomas tend to be caught thinner than the first, probably because survivors are under closer surveillance. Several sets of follow-up guidelines recommend combining time-limited clinical follow-up with lifelong self-examination of the skin.21PubMed Central. Surveillance After a Previous Cutaneous Melanoma Diagnosis: A Scoping Review of Melanoma Follow-Up Guidelines
The psychological burden is real, too. A melanoma diagnosis triggers anxiety, distress, fear of recurrence, and body image concerns, and these reactions do not necessarily fade once treatment ends.22PubMed Central. Exploring the Psychological Experiences of Patients With Melanoma: A Narrative Review As survival rates improve, clinicians are paying more attention to these survivorship issues, recognizing that quality of life after melanoma matters alongside the oncologic outcome.23PubMed. Psychological and behavioral symptoms in patients with melanoma: A systematic review and meta-analysis If you find yourself struggling with persistent worry after a melanoma diagnosis, that is common and worth raising with your care team.
Genetic Risk and Family History
Most melanomas arise from a combination of UV exposure and bad luck, with an estimated 60% to 70% of cases linked to ultraviolet radiation.24PubMed Central. UVA Radiation, DNA Damage, and Melanoma – Section: 2 Risk Factors for Melanoma But a minority of cases cluster in families due to inherited gene mutations, most commonly in a gene called CDKN2A. Mutations in CDKN2A are found in roughly 20% to 40% of melanoma families and are associated with a lifetime melanoma risk between 28% and 67%, depending on the population studied and the specific mutation involved.25PubMed Central. Familial Melanoma: Diagnostic and Management Implications26PubMed Central. CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes People with this mutation may also face elevated risks for pancreatic cancer, a combination sometimes called melanoma-pancreatic syndrome.
If you have two or more close relatives with melanoma, or you yourself have had multiple primary melanomas, genetic testing for CDKN2A and related genes may be worth discussing with a genetic counselor. A positive result does not guarantee cancer, but it intensifies the surveillance: more frequent skin exams, possibly starting at a younger age, and potentially screening for pancreatic cancer as well.
Melanoma in Skin of Color
There is a dangerous misconception that people with darker skin do not get melanoma. They do, and when they do, it tends to be diagnosed at a more advanced stage and carries worse survival rates. The distribution of melanoma subtypes differs across racial groups: acral lentiginous melanoma, which appears on the palms, soles, and under fingernails, and mucosal melanoma, which arises inside the mouth, nose, or genitals, represent a much higher share of melanoma diagnoses in people with skin of color.27PubMed. Melanoma in skin of color: Part I. Epidemiology and clinical presentation These locations are easily overlooked during routine skin checks and are not driven by UV exposure in the same way as melanomas on sun-exposed skin.
For anyone, regardless of skin tone, paying attention to new or changing spots on the palms, soles, and nail beds is a simple screening habit that costs nothing and could catch a cancer that traditional “mole checks” miss entirely.